Gunnar Brinkmalm1,2, Simon Sjödin1,2, Anja Hviid Simonsen3, Steen Gregers Hasselbalch3, Henrik Zetterberg1,2,4,5, Ann Brinkmalm1,2, Kaj Blennow1,2. 1. Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden. 2. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 3. Danish Dementia Research Centre, Rigshospitalet, Copenhagen University, Copenhagen, Denmark. 4. Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, UK. 5. UK Dementia Research Institute, London, UK.
Abstract
SCOPE: The aim of this study was to develop and evaluate a parallel reaction monitoring mass spectrometry (PRM-MS) assay consisting of a panel of potential protein biomarkers in cerebrospinal fluid (CSF). EXPERIMENTAL DESIGN: Thirteen proteins were selected based on their association with neurodegenerative diseases and involvement in synaptic function, secretory vesicle function, or innate immune system. CSF samples were digested and two to three peptides per protein were quantified using stable isotope-labeled peptide standards. RESULTS: Coefficients of variation were generally below 15%. Clinical evaluation was performed on a cohort of 10 patients with Alzheimer's disease (AD) and 15 healthy subjects. Investigated proteins of the granin family exhibited the largest difference between the patient groups. Secretogranin-2 (p<0.005) and neurosecretory protein VGF (p<0.001) concentrations were lowered in AD. For chromogranin A, two of three peptides had significantly lowered AD concentrations (p<0.01). The concentrations of the synaptic proteins neurexin-1 and neuronal pentraxin-1, as well as neurofascin were also significantly lowered in AD (p<0.05). The other investigated proteins, β2-microglobulin, cystatin C, amyloid precursor protein, lysozyme C, neurexin-2, neurexin-3, and neurocan core protein, were not significantly altered. CONCLUSION AND CLINICAL RELEVANCE: PRM-MS of protein panels is a valuable tool to evaluate biomarker candidates for neurodegenerative disorders.
SCOPE: The aim of this study was to develop and evaluate a parallel reaction monitoring mass spectrometry (PRM-MS) assay consisting of a panel of potential protein biomarkers in cerebrospinal fluid (CSF). EXPERIMENTAL DESIGN: Thirteen proteins were selected based on their association with neurodegenerative diseases and involvement in synaptic function, secretory vesicle function, or innate immune system. CSF samples were digested and two to three peptides per protein were quantified using stable isotope-labeled peptide standards. RESULTS: Coefficients of variation were generally below 15%. Clinical evaluation was performed on a cohort of 10 patients with Alzheimer's disease (AD) and 15 healthy subjects. Investigated proteins of the granin family exhibited the largest difference between the patient groups. Secretogranin-2 (p<0.005) and neurosecretory protein VGF (p<0.001) concentrations were lowered in AD. For chromogranin A, two of three peptides had significantly lowered AD concentrations (p<0.01). The concentrations of the synaptic proteins neurexin-1 and neuronal pentraxin-1, as well as neurofascin were also significantly lowered in AD (p<0.05). The other investigated proteins, β2-microglobulin, cystatin C, amyloid precursor protein, lysozyme C, neurexin-2, neurexin-3, and neurocan core protein, were not significantly altered. CONCLUSION AND CLINICAL RELEVANCE: PRM-MS of protein panels is a valuable tool to evaluate biomarker candidates for neurodegenerative disorders.
Authors: Qinying Yu; Xiaofang Zhong; Bingming Chen; Yu Feng; Min Ma; Carol A Diamond; Julie S Voeller; Miriam Kim; Kenneth B DeSantes; Christian M Capitini; Neha J Patel; Margo L Hoover-Regan; Michael J Burke; Kimberly Janko; Diane M Puccetti; Chrysanthy Ikonomidou; Lingjun Li Journal: J Proteome Res Date: 2020-05-27 Impact factor: 4.466
Authors: Karolina Minta; Anna Jeppsson; Gunnar Brinkmalm; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Mats Tullberg; Ulf Andreasson Journal: Fluids Barriers CNS Date: 2021-05-13
Authors: Julia Remnestål; Linn Öijerstedt; Abbe Ullgren; Jennie Olofsson; Sofia Bergström; Kim Kultima; Martin Ingelsson; Lena Kilander; Mathias Uhlén; Anna Månberg; Caroline Graff; Peter Nilsson Journal: Transl Neurodegener Date: 2020-06-23 Impact factor: 8.014
Authors: Jonas Nilsson; Gunnar Brinkmalm; Sherif Ramadan; Lisa Gilborne; Fredrik Noborn; Kaj Blennow; Anders Wallin; Johan Svensson; Mohamed A Abo-Riya; Xuefei Huang; Göran Larson Journal: Sci Rep Date: 2019-04-02 Impact factor: 4.379